Visa (V) developed in April a harness that reduces the cost of and time it takes for Anthropic's Mythos AI to find and fix cyber security vulnerabilities in its codebases significantly, reports The Information
Newsquawk Staff ·
Visa (V) developed in April a harness that reduces the cost of and time it takes for Anthropic's Mythos AI to find and fix cyber security vulnerabilities in its codebases significantly, reports The Information.
What it means
Internal tooling stories of this kind, a large company building bespoke harnesses around a frontier model for security work, have become a recurring genre as enterprises move from piloting AI to operationalising it, and they have tended to matter more as signals of adoption depth than as standalone catalysts. The relevant read here is twofold: for Visa it speaks to the cost trajectory of maintaining large legacy codebases, where automated vulnerability remediation compresses a labour-intensive line item, though the equity rarely re-rates on engineering efficiency alone; for the model provider it is another data point in the enterprise penetration pattern that has underpinned the private-market narrative around frontier labs. The case distinction worth drawing is between internal productivity use cases, which flow quietly through opex, and productised AI features, which carry revenue implications, and this is the former. Worth watching is whether similar deployments surface at peer financials, which would mark the shift from anecdote to sector practice, and any disclosure in subsequent results on technology spend or headcount mix. As a single-source press report of an internal tool, the headline is incremental rather than market-moving.
Sources
- Newsquawk Weekly Economic Release 26th - 30th October 2026
- Newsquawk European Market Wrap - 23rd October 2026
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)
Related headlines
- Week in Focus 26-30th October 2026: FOMC, BoC, RBNZ, ECB, BoJ Policy Decisions, US PCE2 hours ago
- US Midterm Preview: Democrats Favoured to Flip the House, Senate Too Close to Call5 hours ago
- Newsquawk Daily European Opening News - 23rd October 202612 hours ago
- Indonesia's central bank official says rupiah movement still manageable following MSCI announcement last week and says we will respond if needed to ensure supply and demand in the FX market13 hours ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS1 hour ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 20271 hour ago
- OpenAI reveals plans for an in-house exabyte-scale storage system1 hour ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter1 hour ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)2 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed3 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders4 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer4 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM5 hours ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years5 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months6 hours ago